Physician profile
Peter A Johnson
NPI 1801008776
$5,597.73
in general payments reported to CMS, 2019-2025
26 companies · $686 in 2025
The $686 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $451 · 2021: $383 · 2022: $740 · 2023: $942 · 2024: $1,036 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,311.70 | 2019-2025 | |
| Amgen INC. | $542.12 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $476.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $457.23 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $421.66 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $419.85 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.94 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $297.73 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $268.43 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $229.55 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $173.49 | 2024-2025 | |
| Boston Scientific Corporation | $159.34 | 2019-2025 | General - Brady, Wolverine Coronary Cutting Balloon |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.72 | 2019-2025 | Lifevest |
| Scpharmaceuticals INC. | $93.89 | 2023-2024 | |
| Medicomp INC | $48.87 | 2024 | Telepatch Cardiac Monitor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.43 | 2019-2021 | |
| Esperion Therapeutics, INC. | $47.65 | 2020-2021 | |
| Daiichi Sankyo INC. | $32.11 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $25.10 | 2023 | Inpefa |
| Abbott Laboratories | $24.53 | 2021 | |
| Impulse Dynamics (USA) INC. | $23.28 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $20.21 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $17.42 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $15.55 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.63 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.